Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Micturition Reflex01:26

The Micturition Reflex

1.1K
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
1.1K
Urinary Bladder01:23

Urinary Bladder

1.6K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
1.6K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

313
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
313

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards Objective Programming in SNM Therapy: Development and Validation of a Pelvic Floor Measurement System.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

AI-Based Denoising and Identification of Neuromodulation Lead Locations from Limited Intraoperative Fluoroscopy Images.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Associations Between Emotional Distress and Lower Urinary Tract Symptoms Among Somali Women Who Have Experienced Female Genital Cutting.

Journal of women's health (2002)·2025
Same author

A prospective feasibility study to differentiate sacral neuromodulation lead electrode configurations using motor and sensory thresholds and locations of sensation.

BMC urology·2025
Same author

A Prospective Feasibility Study to Differentiate Sacral Neuromodulation Lead Electrode Configurations Using Motor and Sensory Thresholds and Locations of Sensation.

Research square·2024
Same author

Under-representation of Diversity on American Urological Association and European Association of Urology Guideline Panels.

Urology·2024

Related Experiment Video

Updated: Sep 18, 2025

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

9.7K

Off-Label but On-Target: Sacral Neuromodulation for Neurogenic Bladder Dysfunction.

Keianna Vogel1, Nissrine Nakib2

  • 1Department of Urology, University of Minnesota, Minneapolis, 420 Delaware St SE, MMC 394, MN, 55455, USA.

Current Urology Reports
|June 23, 2025
PubMed
Summary

Sacral neuromodulation (SNM) shows promise for neurogenic bladder dysfunction (NBD) in patients unresponsive to standard treatments. This minimally invasive therapy can improve bladder symptoms and function, offering a new management option.

Keywords:
Lower urinary tract dysfunctionNeurogenic bladderSacral neuromodulation

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.4K
Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice
03:26

Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice

Published on: August 1, 2025

180

Related Experiment Videos

Last Updated: Sep 18, 2025

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

9.7K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.4K
Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice
03:26

Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice

Published on: August 1, 2025

180

Area of Science:

  • Neurology
  • Urology
  • Biomedical Engineering

Background:

  • Neurogenic bladder dysfunction (NBD) is a common complication of various neurological disorders.
  • Management of NBD is challenging, particularly for patients refractory to conventional therapies.

Purpose of the Study:

  • To review the emerging role of sacral neuromodulation (SNM) as an off-label treatment for neurogenic bladder dysfunction.
  • To explore the efficacy and potential of SNM in managing refractory NBD.

Main Methods:

  • Review of recent studies, case series, and retrospective analyses on SNM for NBD.
  • Examination of technological advancements in SNM devices.

Main Results:

  • SNM demonstrated improvements in lower urinary tract symptoms, bladder storage, and emptying in select NBD patients.
  • Evidence suggests reduced reliance on catheterization and medication with SNM.
  • Technological innovations are expanding the clinical applicability of SNM.

Conclusions:

  • Sacral neuromodulation is an emerging, minimally invasive treatment for neurogenic bladder dysfunction.
  • Careful patient selection and understanding of pathophysiology are crucial for successful SNM outcomes.
  • Continued evidence and device innovation may significantly alter NBD management strategies.